18677-48-0Relevant articles and documents
An improved procedure for the synthesis of enaminones - Dimer building blocks in β-strand mimetics
Larsson, Andreas,Spjut, Sara,Kihlberg, Jan,Almqvist, Fredrik
, p. 2590 - 2596 (2005)
@-Tides have been shown to have the same characteristics as a peptide in the β-strand conformation and to have the ability to self-associate into dimeric β-sheets. Aza-cyclohexaenaminones, obtained by condensation of a protected azacyclohexa-3,5-dione and amino acid esters, are the key building-blocks in the synthesis of @-tides. An improved three-step synthetic sequence to these enaminones has been developed that takes advantage of microwave-assisted chemistry in two of the steps to enhance the reaction rates. It was also found that the enaminone building blocks can be obtained by direct condensation of the aza-cyclohexa-3,5-dione with amino acid esters, without prior activation of the diketone. Multivariate design was used to optimize this microwave-assisted condensation, resulting in a short reaction time (300 s) and high yields (67-94%). Georg Thieme Verlag Stuttgart.
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin
Metcalf, Brian,Chuang, Chihyuan,Dufu, Kobina,Patel, Mira P.,Silva-Garcia, Abel,Johnson, Carl,Lu, Qing,Partridge, James R.,Patskovska, Larysa,Patskovsky, Yury,Almo, Steven C.,Jacobson, Matthew P.,Hua, Lan,Xu, Qing,Gwaltney, Stephen L.,Yee, Calvin,Harris, Jason,Morgan, Bradley P.,James, Joyce,Xu, Donghong,Hutchaleelaha, Athiwat,Paulvannan, Kumar,Oksenberg, Donna,Li, Zhe
supporting information, p. 321 - 326 (2017/03/17)
We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ~150. This partitioning onto the target protein is anticipated to allow therapeutic concentrations to be achieved in the red blood cell at low plasma concentrations. GBT440 (36) is in Phase 3 clinical trials for the treatment of sickle cell disease (NCT03036813).
SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
-
Paragraph 0315, (2013/07/19)
Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.